Research retrospective · CelluPep editorial synthesis. Cover: AI-generated concept, not experimental data, an exact molecular structure or a photograph of our facilities.
A different endpoint changes the discussion
Peptide research is often summarized through changes in body weight. The SELECT trial asked a different question: whether semaglutide added to standard care could reduce major cardiovascular events in people with established cardiovascular disease and overweight or obesity, but without diabetes. This article revisits the 2023 publication rather than announcing a new result.
The result in its study population
SELECT randomized 17,604 participants. Its primary composite endpoint included cardiovascular death, nonfatal myocardial infarction and nonfatal stroke. Events occurred in 6.5{46d95d0f42d30cedce377123907797bfa6fd9325ccb788643c13db02acfbe38c} of the semaglutide group and 8.0{46d95d0f42d30cedce377123907797bfa6fd9325ccb788643c13db02acfbe38c} of the placebo group; the reported hazard ratio was 0.80. Mean follow-up was 39.8 months. Adverse events leading to permanent treatment discontinuation were more frequent with semaglutide. The benefits and tolerability findings need to be read together. Read the trial.
Why population and outcome matter
The 2021 STEP 1 publication focused on weight change in adults with overweight or obesity without diabetes. It provides another important part of the evidence, but its primary question is not the same as SELECT’s cardiovascular-event question. A weight outcome and an event outcome should therefore remain separately labeled in a literature summary. Read STEP 1.
Our guide to discussing percentages
When preparing a research note, place the event proportions next to the reported effect measure. A hazard ratio and an absolute percentage-point difference are not interchangeable descriptions. Also keep the time horizon and patient population visible. We suggest avoiding a standalone statement such as ‘reduces risk by 20{46d95d0f42d30cedce377123907797bfa6fd9325ccb788643c13db02acfbe38c}’ without explaining which risk, in whom and over what observation period.
Do not extend the finding beyond its evidence
This trial cannot establish the performance of an uncharacterized research material or imply identical results for every GLP-1-related compound. It is not evidence for unsupervised use by otherwise healthy individuals. Clinical decisions require appropriately authorized medicines and qualified medical care; a catalog entry and a clinical trial are different kinds of information.
The takeaway for readers
Organize peptide evidence by the question tested. A clear record of endpoint, population, comparator and uncertainty is more informative than combining distinct findings into a broad wellness claim.
References & further reading
1. Lincoff et al. (2023), NEJM. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
2. Wilding et al. (2021), NEJM. Once-Weekly Semaglutide in Adults with Overweight or Obesity.
Research-use notice
This is an educational interpretation of published research, not an original CelluPep study, a systematic review or medical advice. Clinical trial results do not validate research-use materials sold under the same compound name. No human or veterinary administration is intended. Consult the cited publications for methods, funding, disclosures and full limitations.
For material documentation, visit our Downloads & COA library.
